Irresectable stage III and stage IV melanoma MedDRA version: 20.0 Level: LLT Classification code 10027481 Term: Metastatic melanoma System Organ Class: 100000004864
Conditions
Interventions
Product Name: Pembrolizumab
Product Code: MK3475
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: PEMBROLIZUMAB
CAS Number: 1374853-91-4
Current Sponsor code: MK-3475
Other descriptive
Sponsors
Antoni van leeuwenhoek ziekenhuis
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • Adults at least 18 years of age • World Health Organization (WHO) Performance Status 0-2 • Histologically/cytologically confirmed irresectable stage III or stage IV BRAF V600E or K metastatic melanoma • Measurable disease according to RECIST 1.1 • At least one easy accessible lesion (s.c., lymph node) that can be repeatedly biopsied • Patient willing to undergo triple tumor biopsies during screening, at week 6, week 8 (cohorts 2-4 only), week 12, at week 18, and in case of disease progression • No prior immunotherapy targeting PD-1 or PD-L1 (CTLA-4 targeting therapy is allowed) • No prior BRAF and/or MEK targeting therapy • No immunosuppressive medications • Screening laboratory values must meet the following criteria: WBC = 2.0x109/L, Neutrophils = 1.0x109/L, Platelets = 100 x109/L, Hemoglobin = 5.0 mmol/L Creatinine = 2x ULN AST, ALT = 2.5 x ULN (=5 x ULN for patients with liver metastases) Bilirubin =2 X ULN • Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. • Women of child bearing potential must agree to use a reliable form of contraceptive during the study treatment period and for at least 120 days following the last dose of study drug • Men must agree to the use of male contraception during the study Treatment Period and for at least 180 days after the last dose of study drug. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 28 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 4
Exclusion criteria
Exclusion criteria: • Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment. • Presence of symptomatic brain or leptomeningeal metastases; patients with asymptomatic brain metastases detected during screening for this study are allowed to participate in this study • Prior PD-1/PD-L1 targeting immunotherapy • Has an active automimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjorgen’s syndrome will not be excluded from the study. • Has had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier. • Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to a previously administered agent. - Note: Subjects with = Grade 2 neuropathy are an exception to this criterion and may qualify for the study. - Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy. • Has evidence of interstitial lung disease or active, non-infectious pneumonitis. • Known history of Human Immunodeficiency Virus; • Active infection requiring therapy, positive tests for Hepatitis B surface antigen or Hepatitis C ribonucleic acid (RNA); • Has active tuberculosis • Has received a live vaccine within 30 days prior to the first dose of trial treatment. • Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy. • Underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity determination or adverse events; • Concurrent medical condition requiring the use of immunosuppressive medications, or • Immunosuppressive doses of systemic or absorbable topical corticosteroids • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Secondary Objective: - To determine rates of response at week 6, 12, week 18, and best overall response. - To determine progression-free survival starting from randomization. - To determine long-term toxicities of intermittent dabrafenib + trametinib during treatment with pembrolizumab as compared to pembrolizumab monotherapy ;Main Objective: To explore the safety, feasibility, and the immune-activating capacity of different schemes of continuous/intermittent dabrafenib+trametinib during treatment with pembrolizumab as compared to pembrolizumab monotherapy;Primary end point(s): - Safety and feasibility as measured by SUSARs and adherence to the timelines of the study protocol (week 0 till week 18). - Alterations in percentage of tumor infiltrating CD8+ T cells and in percentage of PD-1+CD8+ T cells in peripheral blood samples in the time interval pre-treatment to week 18 intrapatient, and interpatient, pembrolizumab only (cohort 1) versus pembrolizumab plus intermittent dabrafenib/ trametinib (cohorts 2-4). ;Timepoint(s) of evaluation of this end point: This endpoint will be evaluated during treatment (safety) and at 18 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Secondary endpoints: - Rates of response at week 6, week 12, week 18, and best overall response, according to RECIST 1.1 criteria - Progression-free survival (PFS) starting from randomization to progression using RECIST 1.1 criteria. - Rate and type of late adverse events (beyond week 18, for up to 2 years) Exploratory endpoints: - As the short addition of dabrafenib+trametinib will induce for short time tumor regressions we will analyze cohorts 2-4 with a second baseline, namely the end of the targeted therapy at week 12, for progression free survival using to RECIST 1.1 - In addition to the primary readout (broadening of the melanoma-specific T cell response in peripheral blood), we will analyze the effect of the different therapy schemes on tumor immune cell infiltration (IHC for CD3, CD4, CD8, CD68, FoxP3, PD-L1, PD-L2, PD-1, CD11b, HLA). ;Timepoint(s) of evaluation of this end point: These endpoints will be evaluated during treatment (rate and type of late adverse events) and in the years after the trial. | — |
Countries
Netherlands
Contacts
Public ContactLoes Pronk
Antoni van leeuwenhoek ziekenhuis
Outcome results
None listed